Company research
Cullinan Therapeutics, Inc.
CIK 1789972Updated Nov 11, 2026
SecurityCGEM · NASDAQ · equity
Name history
Cullinan Oncology, Inc. · through Apr 2, 2024Cullinan Management, Inc. · through Feb 22, 2021Cullinan Oncology, LLC · through Jan 6, 2021
CGEM price & chart
Loading TradingView…
NASDAQ:CGEM on TradingView ↗About the company
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
In the news
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G - filed by STATE STREET CORP regarding Cullinan Therapeutics, Inc.
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
144 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 484,126,000Source | 653,254,000Source | 363,787,000Source | 520,329,000Source | 681,216,000Source | 402,984,000Source | 579,681,000Source | 449,430,000Source | 448,374,000Source | 621,824,000Source | 484,182,000Source | 561,117,000Source |
| Property, Plant and Equipment, NetUSD | 489,000Source | 760,000Source | 263,000Source | 569,000Source | 836,000Source | 342,000Source | 607,000Source | 913,000Source | 421,000Source | 683,000Source | 989,000Source | 1,174,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 103,335,000Source | 102,085,000Source | 78,640,000Source | 72,820,000Source | 115,021,000Source | 75,081,000Source | 76,655,000Source | 74,228,000Source | 88,332,000Source | 83,005,000Source | 98,434,000Source | 156,152,000Source |
| Assets, CurrentUSD | 342,235,000Source | 592,039,000Source | 341,974,000Source | 275,911,000Source | 677,799,000Source | 361,407,000Source | 317,772,000Source | 445,721,000Source | 386,756,000Source | 414,668,000Source | 480,191,000Source | 474,472,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 619,000Source | 619,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,046,000Source | 2,019,000Source | 2,233,000Source | 1,180,000Source | 2,121,000Source | 2,437,000Source | 1,550,000Source | 2,336,000Source | 2,630,000Source | 1,667,000Source | 2,543,000Source | 4,130,000Source |
| Other Assets, NoncurrentUSD | 361,000Source | 460,000Source | 297,000Source | 367,000Source | 460,000Source | 297,000Source | 366,000Source | 460,000Source | 297,000Source | 366,000Source | 459,000Source | 459,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 32,757,000Source | 25,392,000Source | 42,033,000Source | 28,183,000Source | 24,995,000Source | 36,812,000Source | 27,842,000Source | 23,765,000Source | 39,644,000Source | 31,496,000Source | 30,287,000Source | 26,088,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 4,000Source | 6,000Source | 6,000Source | 4,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -537,406,000Source | -320,593,000Source | -691,484,000Source | -486,796,000Source | -280,033,000Source | -637,780,000Source | -416,741,000Source | -238,005,000Source | -588,119,000Source | -368,240,000Source | -200,857,000Source | -47,695,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 973,000Source | 970,000Source | -134,000Source | 607,000Source | -476,000Source | 127,000Source | 505,000Source | -331,000Source | 1,020,000Source | -133,000Source | -129,000Source | -2,601,000Source |
| Stockholders' Equity Attributable to ParentUSD | 451,369,000Source | 627,862,000Source | — | 492,146,000Source | 656,221,000Source | — | 551,839,000Source | 425,665,000Source | 408,730,000Source | 590,328,000Source | 453,703,000Source | 535,029,000Source |
| Additional Paid in Capital, Common StockUSD | 987,796,000Source | 947,479,000Source | 1,013,366,000Source | 978,329,000Source | 936,724,000Source | 1,003,819,000Source | 968,069,000Source | 663,997,000Source | 995,823,000Source | 958,695,000Source | 654,685,000Source | 585,320,000Source |
| Liabilities and EquityUSD | 484,126,000Source | 653,254,000Source | 363,787,000Source | 520,329,000Source | 681,216,000Source | 402,984,000Source | 579,681,000Source | 449,430,000Source | 448,374,000Source | 621,824,000Source | 484,182,000Source | 561,117,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 32,757,000Source | 24,204,000Source | 40,628,000Source | 28,058,000Source | 23,476,000Source | 35,154,000Source | 27,349,000Source | 21,925,000Source | 37,741,000Source | 30,647,000Source | 28,137,000Source | 22,498,000Source |
| Operating Lease, Liability, CurrentUSD | 1,188,000Source | 1,258,000Source | 666,000Source | 1,394,000Source | 1,215,000Source | 725,000Source | 1,347,000Source | 1,329,000Source | 780,000Source | 1,302,000Source | 1,440,000Source | 1,421,000Source |
| Accounts Payable, CurrentUSD | 1,722,000Source | 2,115,000Source | 3,725,000Source | 2,461,000Source | 1,555,000Source | 2,509,000Source | 3,401,000Source | 3,707,000Source | 841,000Source | 1,682,000Source | 2,493,000Source | 2,660,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 1,188,000Source | 1,405,000Source | 125,000Source | 1,519,000Source | 1,658,000Source | 493,000Source | 1,840,000Source | 1,903,000Source | 849,000Source | 2,150,000Source | 3,590,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 192,000Source | 0Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 29,847,000Source | 20,831,000Source | 36,237,000Source | 24,203,000Source | 20,706,000Source | 31,920,000Source | 22,601,000Source | 16,889,000Source | 36,120,000Source | 27,663,000Source | 24,204,000Source | 14,135,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 332,600,000Source | 578,100,000Source | 334,500,000Source | 265,500,000Source | — | 351,900,000Source | 303,800,000Source | — | 377,900,000Source | 399,000,000Source | — | — |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| Short-term InvestmentsUSD | 229,261,000Source | 475,993,000Source | 255,898,000Source | 192,662,000Source | 547,474,000Source | 276,804,000Source | 227,172,000Source | 358,783,000Source | 289,564,000Source | 315,972,000Source | 368,633,000Source | 311,140,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -50,610,000Source | -40,560,000Source | -53,704,000Source | -70,055,000Source | -49,661,000Source | -48,501,000Source | -219,879,000Source | -167,575,000Source | -155,101,000Source | 109,195,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 79,000Source | 76,000Source | 311,000Source | 306,000Source | 310,000Source | 93,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 7,616,000Source | 9,374,000Source | 36,040,000Source | 37,824,000Source | 30,438,000Source | 27,957,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,667,000Source | 1,720,000Source | -839,000Source | -812,000Source | -167,000Source | -509,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 3,000,000Source | 5,400,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -46,045,000Source | -43,155,000Source | -175,750,000Source | -145,303,000Source | -134,275,000Source | -126,664,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 32,414,000Source | 36,805,000Source | 179,989,000Source | -136,314,000Source | 35,806,000Source | 248,975,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 49,000Source | 0Source | 208,000Source | 1,133,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 380,000Source | 0Source | 1,088,000Source | 266,188,000Source | 40,751,000Source | -25,933,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | — | 32,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 0Source | -2,970,000Source | -2,274,000Source | -4,433,000Source | 37,801,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 9,467,000Source | 9,430,000Source | 8,447,000Source | 9,887,000Source | 7,616,000Source | 9,374,000Source | 36,040,000Source | 37,824,000Source | 30,438,000Source | 27,957,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 332,600,000Source | 578,100,000Source | 334,500,000Source | 265,500,000Source | 351,900,000Source | 303,800,000Source | 377,900,000Source | 399,000,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 300,000Source | 300,000Source | 300,000Source | 100,000Source |
| Dividends PayableUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 77,000Source |
| General and Administrative ExpenseUSD | — | — | 13,627,000Source | 13,349,000Source | 12,817,000Source | 14,768,000Source | 11,574,000Source | 13,537,000Source | 54,246,000Source | 54,016,000Source | 42,493,000Source | 40,189,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 117,000Source | -14,122,000Source | 42,121,000Source |
| Investment Income, InterestUSD | — | — | 5,093,000Source | 8,384,000Source | 3,648,000Source | 5,924,000Source | 4,098,000Source | 6,580,000Source | 22,212,000Source | 29,660,000Source | 21,627,000Source | 6,611,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -50,610,000Source | -40,560,000Source | — | -70,055,000Source | — | -48,501,000Source | -219,879,000Source | -167,383,000Source | -153,162,000Source | 111,214,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -192,000Source | -1,939,000Source | -2,019,000Source |
| Operating ExpensesUSD | — | — | 55,595,000Source | 48,855,000Source | 57,254,000Source | 75,798,000Source | 53,697,000Source | 54,996,000Source | 241,648,000Source | 196,919,000Source | 190,649,000Source | 132,137,000Source |
| Operating Lease, ExpenseUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 1,200,000Source | 1,200,000Source | 1,700,000Source | 1,100,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -108,000Source | -89,000Source | -98,000Source | -181,000Source | -62,000Source | -85,000Source | -443,000Source | -199,000Source | 239,000Source | 57,000Source |
| Proceeds from Contributions from ParentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 1,153,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 262,652,000Source | 38,388,000Source | 6,020,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Operating Income (Loss)USD | — | — | -55,595,000Source | -48,855,000Source | -57,254,000Source | -75,798,000Source | -53,697,000Source | -54,996,000Source | -241,648,000Source | -196,919,000Source | -191,089,000Source | 144,648,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -108,000Source | -89,000Source | -98,000Source | -181,000Source | -62,000Source | -85,000Source | -443,000Source | -199,000Source | 239,000Source | 57,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -219,879,000Source | -167,458,000Source | -169,223,000Source | 151,316,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 117,000Source | -14,122,000Source | 42,121,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | 0Source | 0Source | — | 0Source | — | 0Source | 0Source | -192,000Source | -1,939,000Source | -2,019,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -50,610,000Source | -40,560,000Source | — | -70,055,000Source | — | -48,501,000Source | -219,879,000Source | -167,383,000Source | -153,162,000Source | 111,214,000Source |
| Earnings Per Share, BasicUSD per share | — | — | — | -0.69Source | — | — | — | — | — | — | -3.69Source | 2.46Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -0.69Source | — | — | — | — | — | — | -3.69Source | 2.38Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 58,337,000Source | — | — | — | — | — | — | 41,550,000Source | 45,164,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 58,337,000Source | — | — | — | — | — | — | 41,550,000Source | 46,640,000Source |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 100,000Source | 14,100,000Source | 42,100,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 300,000Source | 300,000Source | 300,000Source | 100,000Source |
| General and Administrative ExpenseUSD | — | — | 13,627,000Source | 13,349,000Source | 12,817,000Source | 14,768,000Source | 11,574,000Source | 13,537,000Source | 54,246,000Source | 54,016,000Source | 42,493,000Source | 40,189,000Source |
| Investment Income, InterestUSD | — | — | 5,093,000Source | 8,384,000Source | 3,648,000Source | 5,924,000Source | 4,098,000Source | 6,580,000Source | 22,212,000Source | 29,660,000Source | 21,627,000Source | 6,611,000Source |
| Operating ExpensesUSD | — | — | 55,595,000Source | 48,855,000Source | 57,254,000Source | 75,798,000Source | 53,697,000Source | 54,996,000Source | 241,648,000Source | 196,919,000Source | 190,649,000Source | 132,137,000Source |
| Operating Lease, ExpenseUSD | — | — | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 300,000Source | 1,200,000Source | 1,200,000Source | 1,700,000Source | 1,100,000Source |
| Research and Development ExpenseUSD | — | — | 41,968,000Source | 35,506,000Source | 44,437,000Source | 61,030,000Source | 42,123,000Source | 41,459,000Source | 187,402,000Source | 142,903,000Source | 148,156,000Source | 91,948,000Source |
| Other Income | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Offerings
Registration 333-295363
Filing attachments
cgem-ex99_1.htm · 8-K · 2026-11-10
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in December Velinotamig (BCMA TCE) data presented at ACR Convergence 2026; global Phase 1/2 study in autoimmune cytopenias initiated CLN-049 (FLT3 TCE) potentially registrational Phase 2 study in R/R AML underway; updated data from the Phase 1 dose escalation study will be presented at the 2026 ASH Annual M…
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-11-09
Exhibit 99.1 Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026 Clinically meaningful improvement in disease activity among 8 of 9 evaluable patients, including rapid and marked reductions in proteinuria with complete renal responses Deep and sustained reduction in pathogenic autoantibodies and IgG reduction underscore potential in plasma-cell driven dise…
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-11-04
Exhibit 99.1 Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that two of its T cell engager programs, CLN-049, a FLT3xCD3…
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-10-02
Exhibit 99.1 New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission …
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-09-24
Exhibit 99.1 Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December CAMBRIDGE, Mass. September 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “C…
Read attachment ↗cgem-ex99_1.htm · 8-K · 2026-09-14
EX-99.1 2 cgem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Results from the Phase 3 REZILIENT3 trial were featured in a Presidential Symposium at WCLC 2026 and demonstrated a statistically significant improvement in progression-free survival in first-line EGFR exon 20 insertion mutation NSCLC at a plan…
Read attachment ↗